Study of N-Acetylcysteine (NAC) and Continuous Renal Replacement Therapy (CRRT) for the Treatment of Rhabdomyolysis
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
Rhabdomyolysis has many causes including trauma, muscle crush injuries, lack of blood supply
to an arm or leg, burns, seizures, drugs and hereditary disorders. Rhabdomyolysis causes the
breakdown of muscle cells and the release of a molecule called myoglobin. Myoglobin is very
harmful to the kidneys and can lead to kidney failure.
Continuous dialysis has been shown to remove the myoglobin molecule from the blood in
patients with rhabdomyolysis. N-Acetylcysteine (NAC) has been used in patients receiving
contrast dye for x-rays and has shown less worsening of kidney function compared to patients
not receiving NAC.
Early and aggressive treatment of patients with rhabdomyolysis with standard therapy,
continuous dialysis and a drug called N-acetylcysteine (NAC) may prevent the development of
acute kidney failure. Patients who develop kidney failure from this disorder are often
critically ill and have a much higher chance of not surviving than those who do not develop
kidney failure.
The purpose of this study is to determine if the use of NAC and Continuous Veno-Venous
hemo(dia)filtration (CRRT)early in the course of rhabdomyolysis (in addition to standard
therapy)decreases the chance of developing acute renal failure